MSD Korea to recruits subjects with advanced multiple myeloma
Published: 2009-01-09 06:59:00
Updated: 2009-01-09 06:59:00
MSD Korea said on January 7 that it will conduct its local phase 3 and Phase 2b Studies in seven universities hospitals for Merck & Co’s Zolinza (vorinostat), Merck’s oral histone deacetylase (HDAC) inhibitor, in patients with advanced multiple myeloma.
Results from two Phase 1 studies of ZOLI...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
